Unicycive Therapeutics (UNCY) EVP receives 169,500 RSU equity award

Rhea-AI Filing Summary

Jermasek Douglas reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics EVP Douglas Jermasek received a grant of 169,500 restricted stock units payable in common stock. According to the award terms, 23,542 shares vest immediately on grant and 4,708 shares vest monthly over 31 months beginning on June 1, 2026, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jermasek Douglas

Role EVP, Corporate Strategy

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	169,500	$0.00	--

Holdings After Transaction: Restricted Stock Units — 169,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 169,500 units Immediate vesting portion: 23,542 shares Monthly vesting tranche: 4,708 shares +2 more

5 metrics

RSU grant size 169,500 units Restricted stock units granted to EVP Douglas Jermasek

Immediate vesting portion 23,542 shares Portion of RSU award vesting upon grant

Monthly vesting tranche 4,708 shares Monthly vesting over 31 months beginning June 1, 2026

Post-transaction holdings 169,500 shares Underlying common shares following RSU grant

Transaction price per unit $0.0000 Indicates RSU grant at no cash cost to insider

Key Terms

Restricted Stock Units, RSU Award, vest monthly

3 terms

Restricted Stock Units financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU Award financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

vest monthly financial

"4,708 shares vest monthly over 31 months beginning June 1, 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 05:24 PM Accepted by SEC EDGAR 06/15/2026 - 05:23 PM Learn about SEC filing dates

FAQ

What insider transaction did Unicycive Therapeutics (UNCY) report for Douglas Jermasek?

Unicycive Therapeutics reported that EVP of Corporate Strategy Douglas Jermasek received a grant of 169,500 restricted stock units. These units are payable in common stock and represent equity-based compensation rather than an open-market stock purchase or sale.

How many Unicycive (UNCY) restricted stock units were granted in this Form 4/A?

The filing shows a grant of 169,500 restricted stock units to Douglas Jermasek. This entire award is structured as equity compensation, with all 169,500 units tied to Unicycive’s common stock, subject to the specific vesting schedule disclosed.

What is the vesting schedule for Douglas Jermasek’s Unicycive (UNCY) RSU award?

The RSU award vests in two parts: 23,542 shares vest upon grant, and 4,708 shares vest monthly over 31 months starting June 1, 2026. Vesting is conditioned on Jermasek’s continued service with Unicycive Therapeutics.

Did Douglas Jermasek buy or sell Unicycive (UNCY) shares in the market?

The Form 4/A reflects a grant of restricted stock units as compensation, not an open-market trade. Transaction code “A” and a price of $0.0000 per unit indicate an award acquisition rather than a purchase or sale at market prices.

What are Douglas Jermasek’s Unicycive (UNCY) holdings after this RSU transaction?

After the reported transaction, the filing lists 169,500 underlying common shares associated with Douglas Jermasek’s restricted stock units. This figure represents his position related to this award following the grant, as disclosed in the ownership table.

Are there any unexercised derivative positions disclosed for Douglas Jermasek in this Unicycive filing?

The derivative summary in the filing is empty, indicating no additional derivative positions such as options or warrants reported beyond this restricted stock unit grant. The only derivative transaction shown is the 169,500-unit RSU award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jermasek Douglas

(Last) (First) (Middle)

C/O UNICYCIVE THERAPEUTICS, INC.

1975 W. EL CAMINO REAL, SUITE 204

(Street)

MOUNTAIN VIEW CALIFORNIA 94040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corporate Strategy

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/20/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	05/14/2026		A		169,500		(1)	(1)	Common Stock	169,500	$0	169,500	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

	/s/ Doug Jermasek	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)